Stockscreener 앱 받기
584.79
3.78%
21.30
시간 외 거래:
584.79
전일 마감가:
$563.49
열려 있는:
$568.69
하루 거래량:
878.42K
Relative Volume:
1.39
시가총액:
$25.08B
수익:
$3.17B
순이익/손실:
$1.29B
주가수익비율:
21.58
EPS:
27.0947
순현금흐름:
$1.01B
1주 성능:
+7.99%
1개월 성능:
+17.52%
6개월 성능:
+1.83%
1년 성능:
+38.69%
1일 변동 폭
$562.86
$590.79
1주일 범위
$534.61
$590.79
52주 변동 폭
$409.07
$609.35
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, TEVA, HLN, ZTS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
584.79 | 25.08B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
20.36 | 65.04B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
40.21 | 46.90B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.37 | 45.60B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
82.00 | 33.88B | 9.51B | 2.64B | 2.14B | 6.0361 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-01 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2026-09-24 | 개시 | Goldman | Sell |
| 2026-05-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2026-04-10 | 개시 | Raymond James | Outperform |
| 2025-10-20 | 개시 | Wells Fargo | Underweight |
| 2025-09-26 | 개시 | RBC Capital Mkts | Outperform |
| 2025-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-02-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-12-05 | 개시 | Goldman | Sell |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-20 | 재확인 | BofA Securities | Underperform |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-02-11 | 개시 | BTIG Research | Neutral |
| 2021-07-14 | 업그레이드 | Argus | Hold → Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
| 2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 개시 | BofA/Merrill | Underperform |
| 2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
| 2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 재확인 | Barclays | Underweight |
| 2018-01-18 | 재개 | Credit Suisse | Underperform |
| 2017-12-27 | 재확인 | Wedbush | Outperform |
| 2017-04-27 | 재확인 | Wedbush | Outperform |
| 2017-03-30 | 개시 | UBS | Sell |
| 2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
United Therapeutics Authorizes Up to $2 Billion Share Repurchase - TradingView
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization - Yahoo Finance
United Therapeutics CEO Martine Rothblatt sells $5.26m in stock - Investing.com
CEO trusts sell 9,500 United Therapeutics (UTHR) shares after exercising stock options. - Stock Titan
United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026 - Yahoo Finance
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 19 October - Investing.com Nigeria
United Therapeutics CEO Rothblatt sells $5.16m in shares - Investing.com
United Therapeutics (UTHR): Can the Profit-Machine Biotech Finally Crack the S&P 500? - Yahoo Finance
United Therapeutics opens third xenograft production facility - Investing.com
A Houston site is built to make pig kidneys and hearts for United Therapeutics’ organ program. - Stock Titan
United Therapeutics opens xeno-organ facility in Generation Park, marking Houston's continued pharma growth - The Business Journals
United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility - Yahoo Finance
United Therapeutics chairperson & CEO sells $5.08m in shares By Investing.com - Investing.com Nigeria
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 16 October - Investing.com Nigeria
After exercising options at $117.76, CEO trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years - Benzinga
Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years - Benzinga
United Therapeutics (UTHR) Gains FDA Approval for SUMMIT Trial o - GuruFocus
Up to 800,000 people have high blood pressure in the lungs linked to chronic lung disease. An inhaler trial can proceed. - Stock Titan
United Therapeutics (NASDAQ:UTHR): A GARP Case Built on Durable Growth at a Reasonable Price - ChartMill
United Therapeutics chairperson & CEO sells $5.19m in stock - Investing.com
Paul Mahon, United Therapeutics EVP, sells $4.5m in stock - Investing.com
After exercising options at $117.76 each, CEO trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
An 8,300-share planned sale follows an option exercise by United Therapeutics (UTHR) counsel. - Stock Titan
United Therapeutics CEO Rothblatt sells $5.1m in shares By Investing.com - Investing.com Nigeria
After exercising options at $117.76, United Therapeutics (UTHR) CEO family trusts sell 9,500 shares. - Stock Titan
A CEO trust exercises options at $117.76 and sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
United Therapeutics secures $381M settlement in patent dispute with competitor - The Business Journals
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label - Zacks Investment Research
Liquidia shares surge 25% as settlement ends United Therapeutics litigation - Yahoo Finance
SGIOY or UTHR: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Why Is Liquidia Stock Skyrocketing Wednesday?United Therapeutics (NASDAQ:UTHR), Liquidia (NASDAQ:LQDA) - Benzinga
Why Investors Need to Take Advantage of These 2 Medical Stocks Now - Zacks Investment Research
A $10M payment is also due from United Therapeutics (UTHR) in its settlement with Liquidia. - Stock Titan
Liquidia shares surge to 5-month high premarket on United Therapeutics settlement - Yahoo Finance
Liquidia Shares Surge 42.48% After HoursUnited Therapeutics (NASDAQ:UTHR), Liquidia (NASDAQ:LQDA) - Benzinga
Liquidia Settles United Therapeutics Suits With $380.7M Deal - Law360
Liquidia Settles United Therapeutics Suits With $380.7M Deal - Law360
Liquidia Just Paid $380 Million to End a Patent War That Crushed the Stock - Money Morning
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH - The Manila Times
Patients with high blood pressure in the lungs will keep access to YUTREPIA as Liquidia settles six lawsuits. - Stock Titan
Martine Rothblatt, United Therapeutics CEO, sells $5.2m in shares - Investing.com
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 12 October - Investing.com Canada
The CEO’s family trust sold 9,500 United Therapeutics (UTHR) shares under a pre-arranged trading plan. - Stock Titan
After exercising options at $117.76, the CEO's trust sold 9,500 United Therapeutics (UTHR) shares. - Stock Titan
United Therapeutics Corporation Presents New Data Across Its Commercial and Development Portfolio At the CHEST 2026 Annual Meeting - marketscreener.com
An inhaled drug still being tested reduced the risk of multiple worsening events for people with lung scarring - Stock Titan
United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting - Yahoo Finance
Form 4 United Therapeutics Corporation For: 12 October By Investing.com - Investing.com UK
United Therapeutics CEO Rothblatt sells $5.2m in stock By Investing.com - Investing.com Nigeria
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
유나이티드 테라퓨틱스 주식 (UTHR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 21 '26 |
Sale |
560.07 |
9,500 |
5,320,681 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 20 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 20 '26 |
Sale |
553.87 |
9,500 |
5,261,741 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 19 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 19 '26 |
Sale |
543.32 |
9,500 |
5,161,576 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 16 '26 |
Sale |
534.66 |
9,500 |
5,079,275 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 16 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| PAUL MAHON | Officer |
Oct 15 '26 |
Proposed Sale |
544.30 |
8,300 |
4,517,709 |
0 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 15 '26 |
Sale |
546.65 |
9,500 |
5,193,200 |
324,443 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Oct 15 '26 |
Option Exercise |
146.03 |
8,300 |
1,212,049 |
53,472 |
0.16%
자본화:
|
볼륨(24시간):